How was ENSPRYNG studied?
ENSPRYNG is the only NMOSD therapy approved based on two clinical trials.
ENSPRYNG is the only NMOSD therapy approved based on two clinical trials.
Two clinical trials were conducted to determine if ENSPRYNG alone or ENSPRYNG plus immunosuppressive therapy (IST) could lower the risk of relapse in adults with NMOSD vs. placebo and vs. placebo plus IST. ISTs may stop some activity in your body's immune system, and can include azathioprine, mycophenolate mofetil, or oral corticosteroids. Both trials also measured how many patients were relapse-free at specific points with treatment.
Learn more about the only self-injectable* NMOSD treatment given under the skin.
*with doctor approval and training
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.